Sandy’s main research interests are the development of new antibody-inducing vaccines and breaking down the barriers to translation of new biological medicines into clinical trials.
Sandy leads the University’s Bioprocess and Analytical Development (BiPAD) team, which is concerned with bringing together clinical and bioprocess understanding to make small-scale GMP manufacturing more cost-effective, lowering the barrier to experimental medicine and early-phase clinical development of novel interventions.